Spontaneous Reporting in the United States

Pharmacoepidemiology, Fourth Edition

Volumn , Issue , 2007, Pages 131-159

  Ahmad, Syed Rizwanuddin ^a   Goetsch, Roger A ^b   Marks, Norman S ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^b Office of Drug Safety (HFD 430)   (United States)

Author keywords

Adverse event recognition; Adverse event reporting system (AERS); Data mining; FDA postmarketing reporting requirement; MedWatch voluntary reporting form; Regulatory reporting requirements; Serious Adverse Drug Reaction (SADR); Spontaneous reporting in US; Spontaneous reporting of AEs

Indexed keywords

EID: 84889452671     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470059876.ch9     Document Type: Chapter

References (92)

1. Faich GA. Adverse-drug-reaction monitoring. N Engl J Med 1986; 314: 1589-92.
2. Faich GA, Milstien JB, Anello C, Baum C. Sources of spontaneous adverse drug reaction reports received by pharmaceutical manufacturers. Drug Info J 1987; 21: 251-5.
3. Knapp DE, Perry ZA. Annual Adverse Drug Reaction Report: 1989. Report of Surveillance Section, Surveillance and Data Processing Branch, Division of Epidemiology and Surveillance, Office of Epidemiology and Biostatistics, Center for Drug Evaluation and Research, FDA.
4. Ahmad SR. Adverse drug event monitoring at the Food and Drug Administration. J Gen Intern Med 2003; 18: 57-60.
5. Laughren T. Premarketing studies in the drug approval process: understanding their limitations regarding the assessment of drug safety. Clin Ther 1998; 20 (suppl C): C12-19.
6. FDA. Managing the Risks from Medical Product Use. Report to the FDA Commissioner from the Task Force on Risk Management. Rockville, MD: Food and Drug Administration, May 1999.
7. Bates DW, Leape LL, Petrycki S. Incidence and preventability of adverse drug events in hospitalized adults. J Gen Intern Med 1993; 8: 289-94.
8. Hilts PJ. Protecting America's Health: The FDA, Business, and One Hundred Years of Regulation. New York: Knopf, 2003.
9. FDA Consumer. The Long Struggle for the 1906 Law, June 1981. Available at: http://www.cfsan.fda.gov/~lrd/history2.html.
10. Jackson CO. Food and Drug Legislation in the New Deal. Princeton, NJ: Princeton University Press, 1970.
11. Maeder T. Adverse Reactions. New York: Morrow, 1994.
12. Moser RH. The obituary of an idea. JAMA 1971; 216: 2135-6.
13. Kerlan I. Reporting adverse reactions to drugs. Bull Am Soc Hosp Pharm 1956; 13: 311-14.
14. FDA. Monthly Report: Adverse Reactions to Drugs and Therapeutic Devices. Report of Adverse Reaction Branch, Division of Medical Information, Bureau of Medicine, August 1965.
15. FDA. Semi-Monthly Adverse Reaction Alert Report and Reactions of Clinical Significance. Report of Division of Drug Experience, October 1968.
16. Adverse experience reporting requirements for licensed biological products: final rule. Fed Regist 1994; 59: 54034-44.
17. Expedited safety reporting requirements for human drug and biological products: final rule. Fed Regist 1997; 62: 52237-53.
18. Dietary Supplement Health and Education Act (DSHEA) of 1994, Public Law 103-417, 103rd Congress.
19. Bren L. FDA's response to food, dietary supplement, and cosmetic adverse events. FDA Consumer July/August, 2003.
20. FDA Center for Drug Evaluation and Research. Guidelines for Postmarketing Reporting of Adverse Drug Experiences. Rockville, MD: CDER, 1992.
21. FDA Center for Drug Evaluation and Research. Guideline for Adverse Experience Reporting for Licensed Biological Products. Rockville, MD: CDER, 1993.
22. FDA. Guideline on Clinical Safety Data Management: Periodic Safety Update Reports for Marketed Drugs, May 19, 1997 Fed Regist 1997; 62: 27470-6.
23. Safe Medical Devices Act of 1990. Public Law 101-629. Stat 1990; 104: 4511.
24. JCAHO. Available at: http://www.hosp.uky.edu/pharmacy/departpolicy/PH03-02.pdf.
25. American Society of Health-System Pharmacists. ASHP Guidelines on Adverse Drug Reaction Monitoring and Reporting. Available at: http://www.ashp.org/bestpractices/MedMis/MedMis_Gdl_ADR.pdf.
26. American Medical Association. Reporting adverse drug and medical device events: report of the AMA's Council on Ethical and Judicial Affairs. Food Drug Law J 1994; 49: 359-66.
27. American Dental Association. Advisory Opinion 5.D.1, Reporting Adverse Reactions. Principles of Ethics and Code of Professional Conduct, January 2004.
28. Anonymous. JAMA instructions for authors. JAMA 2004; 291: 125-30.
29. Glass RM. Reporting of public health hazards or major advances-revision of uniform requirements. JAMA 1998; 280: 2035.
30. Kessler DA. Introducing MedWatch: a new approach to reporting medication and device adverse effects and product problems. JAMA 1993; 269: 2765-829.
31. Ahmad SR. MedWatch. Lancet 1993; 341: 1465.
32. FDA MedWatch. Clinical therapeutics and the recognition of drug-induced disease, MedWatch continuing education article. Available at: http://www.fda.gov/medwatch/articles/dig/ceart.pdf.
33. Protecting the identities of reporters of adverse events and patients: preemption of disclosure rules. Fed Regist 1995; 60: 16962-8.
34. Ahmad SR, Freiman JP, Graham DJ, Nelson RC. Quality of adverse drug experience reports submitted by pharmacists and physicians to the FDA. Pharmacoepidemiol Drug Saf 1996; 5: 1-7.
35. Graham DJ, Ahmad SR, Piazza-Hepp T. Spontaneous Reporting-USA. In: Mann R, Andrews E, eds, Pharmacovigilance. Chichester: John Wiley & Sons, 2002; pp. 219-27.
36. Smalley W, Shatin D, Wysowski DK, Gurwitz J, Andrade SE, Goodman M et al. Contraindicated use of cisapride: impact of food and drug administration regulatory action. JAMA 2000; 284: 3036-9.
37. Graham DJ, Drinkard CR, Shatin D, Tsong Y, Burgess MJ. Liver enzyme monitoring in patients treated with troglitazone. JAMA 2001; 286: 831-3.
38. Brinker AD, Mackey AC, Prizont R. Tegaserod and ischemic colitis (letter). N Engl J Med 2004; 351: 1361-4.
39. Bonnel RA, Graham DJ. Peripheral neuropathy in patients treated with leflunomide. Clin Pharm Therapeutics 2004; 75: 580-5.
40. Griffin MR, Stein CM, Graham DJ, Daugherty JR, Arbogast PG, Ray WA. High frequency of use of rofecoxib at greater than recommended doses: cause for concern. Pharmacoepidemiol Drug Saf 2004; 13: 339-43.
41. Brinker A, Johnston M. Acute pulmonary edema in association with amiodarone. Chest 2004; 125: 1591-2.
42. Wysowski DK, Farinas E. Finasteride and benign prostatic hyperplasia. N Engl J Med 2004; 350: 1359.
43. Fraunfelder FW, Fraunfelder FT, Goetsch RA. Adverse ocular effects and OTC lice shampoo. Arch Ophthalmol 2003; 121: 1790-1.
44. Phelan K, Mosholder A, Lu S. Lithium interaction with the cyclooxygenase 2 inhibitors rofecoxib and celecoxib and other nonsteroidal antiinflammatory drugs. J Clin Psychiatry 2003; 64: 1328-34.
45. Chang JT, Green L, Beitz J. Renal failure with the use of zoledronic acid. N Engl J Med 2003; 349: 1676-8.
46. Ahmad SR, Graham DJ. Pneumonitis with antiandrogens. Ann Intern Med 2003; 139: 3-4.
47. Flowers C, Racoosin J, Lu S, Beitz J. Pergolide-associated valvular heart disease. Mayo Clin Proc 2003; 78: 730-1.
48. Beck P, Wysowski DK, Downey W, Butler-Jones D. Statin use and the risk of breast cancer. J Clin Epidemiol 2003; 56: 280-5.
49. Graham DJ, Green L, Senior JR, Nourjah P. Troglitazone-induced liver failure: a case study. Am J Med 2003; 114: 299-306.
50. Bonnel RA, La Grenade L, Karwoski CB, Beitz J. Allergic contact dermatitis from topical doxepin: Food and Drug Administration's postmarketing surveillance experience. J Am Acad Dermatol 2003; 48: 294-6.
51. Manda B, Drinkard CR, Shatin D, Graham DJ. The risk of esophageal obstruction associated with an anti-allergy medication (Claritin-D 24-Hour-original formulation). Pharmacoepidemiol Drug Saf 2004; 13: 29-34.
52. Graham DJ, Drinkard CR, Shatin D. Incidence of idiopathic acute liver failure and hospitalized liver injury in patients treated with troglitazone. Am J Gastroenterol 2003; 98: 175-9.
53. O'Connell KA, Wilkin JK, Pitts M. Isotretinoin (Accutane) and serious psychiatric adverse events. J Am Acad Dermatol 2003; 48: 306-8.
54. Brinker A, Staffa J. Concurrent use of selected agents with moxifloxacin: an examination of labeling compliance within 1 year of marketing. Arch Intern Med 2002; 162: 2011-2.
55. Kornegay CJ, Vasilakis-Scaramozza C, Jick H. Incident diabetes associated with antipsychotic use in the United Kingdom General Practice Research Database. J Clin Psychiatry 2002; 63: 758-62.
56. Thambi L, Kapcala LP, Chambers W, Nourjah P, Beitz J, Chen M et al. Topiramate-associated secondary angel-closure glaucoma: a case series. Arch Ophthal 2002; 120: 1108.
57. Bonnel RA, Villaba ML, Karwoski CB, Beitz J. Deaths associated with inappropriate intravenous colchicine administration. J Emergency Med 2002; 22: 385-7.
58. Ahmad SR, Kortepeter C, Brinker A, Chen M, Beitz J. Renal failure associated with the use of celecoxib and rofecoxib. Drug Saf 2002; 25: 537-44.
59. Shaffer D, Singer S, Korvick J, Honig P. Concomitant risk factors in reports of torsades de pointes associated with macrolide use: review of the United States Food and Drug Administration Adverse Event Reporting System. Clin Infect Dis 2002; 35: 197-200.
60. Wysowski DK, Honig SF, Beitz J. Uterine sarcoma associated with tamoxifen use. N Engl J Med 2002; 346: 1832-3.
61. Wysowski DK, Farinas E, Swartz L. Comparison of reported and expected deaths in sildenafil (Viagra) users. Am J Cardiol 2002; 89: 1331-4.
62. Brinker A, Bonnel R, Beitz J. Abuse, dependence, or withdrawal associated with tramadol. Am J Psychiatry 2003; 159: 881.
63. Kortepeter C, Chen M, Knudsen JF, Dubitsky GM, Ahmad SR, Beitz J. Clozapine and venous thromboembolism. Am J Psychiatry 2002; 159: 876-7.
64. Bonnel RA, Villalba ML, Karwoski CB, Beitz J. Aseptic meningitis associated with rofecoxib. Arch Intern Med 2002; 162: 713-5.
65. Staffa JA, Chang J, Green L. Cerivastatin and reports of fatal rhabdomyolysis. N Engl J Med 2002; 346: 539-40.
66. Bate A, Lindquist M, Edwards IR, Orre R. A data mining approach for signal detection and analysis. Drug Saf 2002; 25: 393-7.
67. Szarfman A, Machado SG, O'Neill RT. Use of screening algorithms and computer systems to efficiently signal higher-than-expected combinations of drugs and events in the US FDA's spontaneous reports database. Drug Saf 2002; 25: 381-92.
68. Fletcher AP. Spontaneous adverse drug reaction reporting vs event monitoring: a comparison. J R Soc Med 1991; 84: 341-4.
69. Alvarez-Requejo A, Carvajal A, Begaud B, Moride Y, Vega T, Arias LH. Under-reporting of adverse drug reactions: estimate based on a spontaneous reporting scheme and a sentinel system. Eur J Clin Pharmacol 1988; 54: 483-8.
70. Finney DJ. The detection of adverse reactions to therapeutic drugs. Stat Med 1982; 1: 153-61.
71. Strom BL, Tugwell P. Pharmacoepidemiology: current status, prospects, and problems. Ann Intern Med 1990; 113: 179-81.
72. Finney DJ. Statistical aspects of monitoring for dangers in drug therapy. Methods Inf Med 1972; 10: 1-8.
73. Standardization of definitions and criteria of causality assessment of adverse drug reactions: drug-induced liver disorders: report of an international consensus meeting. Int J Clin Pharmacol Ther Toxicol 1990; 28: 317-22.
74. Auriche M, Loupi E. Does proof of causality ever exist in pharmacovigilance? Drug Saf 1993; 9: 230-5.
75. Begaud B, Moride Y, Tubert-Bitter P, Chaslerie A, Haramburu F. False-positives in spontaneous reporting: should we worry about them? Br J Clin Pharmacol 1994; 38: 401-4.
76. Temple RJ, Jones JK, Crout JR. Adverse effects of newly marketed drugs. N Engl J Med 1979; 300: 1046-7.
77. Rawlins MD. Pharmacovigilance: paradise lost, regained or postponed? The William Withering Lecture 1994. J R College Physicians Lond 1995; 29: 41-9.
78. Meyboom RH, Hekster YA, Egberts AC, Gribnau FW, Edwards IR. Causal or casual? The role of causality assessment in pharmacovigilance. Drug Saf 1997; 17: 374-89.
79. Koch-Weser J, Sellers EM, Zacest R. The ambiguity of adverse drug reactions. Eur J Clin Pharmacol 1997; 11: 75-8.
80. Green DM. Pre-existing conditions, placebo reactions, and "side effects." Ann Intern Med 1964; 60: 255-65.
81. Reidenberg MM, Lowenthal DT. Adverse nondrug reactions. N Engl J Med 1968; 279: 678-9.
82. Karch FE, Smith CL, Kerzner B, Mazzullo JM, Weintraub M, Lasagna L. Adverse drug reactions-a matter of opinion. Clin Pharmacol Ther 1976; 19: 489-92.
83. Rogers AS, Israel E, Smith CR. Physician knowledge, attitudes, and behavior related to reporting adverse drug events. Arch Intern Med 1988; 148: 1589-92.
84. Scott HD, Rosenbaum SE, Waters WJ, Colt AM, Andrews LG, Juergens JP et al. Rhode Island physicians' recognition and reporting of adverse drug reactions. R I Med J 1987; 70: 311-16.
85. Goldman SA. Limitations and strengths of spontaneous reports data. Clin Ther 1998; 20 (suppl C): C40-4.
86. Sachs RM, Bortnichak EA. An evaluation of spontaneous adverse drug reaction monitoring systems. Am J Med 1986; 81 (suppl 5B): 49-55.
87. Bhasin S, Reyburn H, Steen J, Waller PC. The effects of media publicity on spontaneous adverse reaction reporting with mefloquine in the UK. Pharmacoepidemiol Drug Saf 1997; 6 (suppl 2): 32.
88. Rossi AC, Hsu JP, Faich GA. Ulcerogenicity of piroxicam: analysis of spontaneously reported data. BMJ 1987; 294: 147-50.
89. Tsong Y. Comparing reporting rates of adverse events between drugs with adjustment for year of marketing and secular trends in total reporting. J Biopharm Stat 1995; 5: 95-114.
90. Weber JCP. Epidemiology of adverse reactions to nonsteroidal antiinflammatory drugs. In: Rainsford KD, Velo GP, eds, Advances in Information Research, vol. 6. New York: Raven, 1984; pp. 1-7.
91. Serradell J, Bjornson DC, Hartzema AG. Drug utilization study methodologies: national and international perspectives. Drug Intell Clin Pharm 1987; 21: 994-1001.
92. Blum MD, Graham DJ, McCloskey CA. Temafloxacin syndrome: review of 95 cases. Clin Infect Dis 1994; 6: 946-50.